Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 10,845 matching trials from the live ClinicalTrials.gov search.
Filters: Columbus, Ohio Clear all
Completed Phase 2 Interventional Results available

Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors

NCT00047320
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumors, Childhood Germ Cell Tumor
Interventions
carboplatin, etoposide, ifosfamide, thiotepa, adjuvant therapy, conventional surgery, neoadjuvant therapy, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 24 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
90
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 79 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 31, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

NCT03845296
View directory record Official record
Conditions
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma, Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Rucaparib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
950
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 630 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 31, 2026, 1:07 AM EDT
Completed Phase 2 Interventional

Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00089154
View directory record Official record
Conditions
Noncontiguous Stage II Small Lymphocytic Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Small Lymphocytic Lymphoma
Interventions
apolizumab, laboratory biomarker analysis, pharmacological study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
La Jolla, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 31, 2026, 1:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Food Survey, Curbside, Remote APPs SC

NCT05963854
View directory record Official record
Conditions
Waste Management, Recycling, Climate, Nutrition Sciences
Interventions
Survey Curbside
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 31, 2026, 1:07 AM EDT
Not yet recruiting Not applicable Interventional

Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell Lung Cancer

NCT06816979
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Lumbar Puncture, Magnetic Resonance Imaging
Procedure · Device
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 31, 2026, 1:07 AM EDT
Completed Phase 2 Interventional

S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer

NCT00003127
View directory record Official record
Conditions
Endometrial Cancer
Interventions
amifostine trihydrate, carboplatin, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
16 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
94
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 31, 2026, 1:07 AM EDT
Terminated Phase 1 Interventional

Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

NCT02474173
View directory record Official record
Conditions
Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Onalespib, Paclitaxel, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Lexington, Kentucky • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 31, 2026, 1:07 AM EDT
Completed Phase 4 Interventional Results available

Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)

NCT00617305
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan, Placebo, Sildenafil, Tadalafil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
30
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 31, 2026, 1:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.

NCT02598960
View directory record Official record
Conditions
Solid Tumors
Interventions
BMS-986156, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
Birmingham, Alabama • La Jolla, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 31, 2026, 1:07 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of OMS103HP in Patients Undergoing Allograft Anterior Cruciate Ligament (ACL) Reconstruction

NCT00226759
View directory record Official record
Conditions
Knee Injuries
Interventions
OMS103HP, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
15 Years to 65 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
18
States / cities
Encinitas, California • Redwood City, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 31, 2026, 1:07 AM EDT
Completed Not applicable Interventional Results available

Rheos® Pivotal Trial

NCT00442286
View directory record Official record
Conditions
Hypertension
Interventions
Rheos® Baroreflex Hypertension System
Device
Lead sponsor
CVRx, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
42
States / cities
Birmingham, Alabama • Inglewood, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 31, 2026, 1:07 AM EDT
Recruiting Not applicable Interventional

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

NCT05080673
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Interventions
5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy
Procedure
Lead sponsor
NRG Oncology
Other
Eligibility
45 Years to 70 Years
Enrollment
9,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2065
U.S. locations
478
States / cities
Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 323 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 31, 2026, 1:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

NCT04037254
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Gonadotrophin Releasing Hormone, Intensity-Modulated Radiation Therapy, Niraparib
Biological · Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
94
States / cities
Gilbert, Arizona • Tucson, Arizona • Duarte, California + 77 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 31, 2026, 1:07 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of FDY-5301 in Major Trauma Patients in ICU

NCT04430283
View directory record Official record
Conditions
ICU Acquired Weakness
Interventions
FDY-5301, Placebo
Drug · Other
Lead sponsor
Faraday Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Torrance, California • Gainesville, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 31, 2026, 1:07 AM EDT
Completed Phase 3 Interventional Results available

TAXUS PERSEUS Small Vessel

NCT00489541
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Bakersfield, California • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 31, 2026, 1:07 AM EDT
Completed Phase 2 Interventional

Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome

NCT00454688
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Asimadoline, Placebo
Drug
Lead sponsor
Tioga Pharmaceuticals
Industry
Eligibility
18 Years to 79 Years
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
112
States / cities
Huntsville, Alabama • Pheonix, Arizona • Phoenix, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2011 · Synced Oct 31, 2026, 1:07 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

NCT03112603
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 31, 2026, 1:07 AM EDT
Withdrawn No phase listed Observational

Safety of Percutaneous Tracheostomy in Clopidogrel and Selective Serotonin Reuptake Inhibitors

NCT02074254
View directory record Official record
Conditions
Tracheostomy Complication
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 31, 2026, 1:07 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

NCT03898479
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 31, 2026, 1:07 AM EDT
Terminated Not applicable Interventional Results available

Preliminary Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low-weight Infants

NCT03982342
View directory record Official record
Conditions
Patent Ductus Arteriosus
Interventions
Cather closure of patent ductus arteriosus (PDA), Conservative management of patent ductus arteriosus (PDA)
Device · Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
14 Days to 28 Days
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Columbus, Ohio • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 31, 2026, 1:07 AM EDT
Completed Phase 3 Interventional Results available

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

NCT00986154
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism, Venous Thrombosis
Interventions
edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
8,292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
82
States / cities
Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 31, 2026, 1:07 AM EDT
Completed Phase 3 Interventional

Study of Fluoxetine in Autism

NCT00515320
View directory record Official record
Conditions
Autistic Disorder
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
Neuropharm
Industry
Eligibility
5 Years to 17 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 31, 2026, 1:07 AM EDT
Completed Phase 3 Interventional Results available

Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ

NCT00438659
View directory record Official record
Conditions
Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
Interventions
mometasone furoate, placebo
Drug · Other
Lead sponsor
North Central Cancer Treatment Group
Network
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
189
States / cities
Aurora, Illinois • Bloomington, Illinois • Canton, Illinois + 116 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 31, 2026, 1:07 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neural and Hormonal Influences on Sex Differences in Risk for AUD

NCT04929288
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Alcohol
Drug
Lead sponsor
Jessica Weafer
Other
Eligibility
21 Years to 26 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 31, 2026, 1:07 AM EDT